ACCESSIBILITY

24/7

Headlines

22:21

Israel faces a new push to shut it out of the EU’s flagship research program

21:33

Nice cuts 500 jobs, but investors may be looking for much deeper changes

20:49

Air Canada returns to Israel with a 30% price increase

20:31

The dollar has reached a six-month high against the shekel. What is driving the move?

Buzz

Most popular

Daily

Weekly

From six-person startups to a $6.3 billion take-private: October's extraordinary month for Israeli tech exits

ServiceNow CEO says acquired Israeli startup Sweep helps it switch CRM customers in weeks, not years

Nice to lay off 500 employees as it struggles to navigate the AI transition

Israeli digital health company TailorMed acquired in $250 million deal

After years of delays, IDF prepares to deploy Elbit’s new Ro'em artillery systems

More news

Teva

20 stories about Teva

Teva returns to profit in Q2 but misses on revenue

30.07.25|Sophie Shulman

Austedo disappoints, while Uzedy and Ajovy drive upside in brand-name drugs.

Teva’s quiet layoff announcement reveals bold restructuring plan

08.05.25|Sophie Shulman

CEO signals this is ‘just the first step’ in multi-year effort to streamline and scale.

מנכ"ל טבע ריצ'רד פרנסיס מפגש עיתונאים 2025

Teva to cut 3,000 jobs by 2027 in drive toward higher profit margins

07.05.25|Sophie Shulman

Pharma giant targets 30% operating margin by laying off approximately 8% of its global workforce as it boosts forecasts on drug sales and updates its "Pivot to Growth" strategy.

לוגו חברת טבע ב מטה החברה ב תל אביב 20.2.24

Teva signals return to fundraising after decade-long crisis

08.02.25|Sophie Shulman

Israeli pharmaceutical giant eyes stock offering as part of its recovery plan.

Teva’s stock surge comes to a halt, falling 14% amid weak 2025 outlook

30.01.25|Sophie Shulman

Despite a strong 80% gain in 2024, Teva’s stock dropped after the company revealed disappointing profitability and cash flow forecasts.

Teva surpasses expectations in Q4 but sets cautious outlook for 2025

29.01.25|Sophie Shulman

Despite a strong finish to the year, Teva forecasts lower-than-expected earnings and revenue growth for 2025.

Teva’s 10-year turnaround takes shape with stunning trial results

18.12.24|Sophie Shulman

Duvakitug signals a brighter future for the Israeli pharma giant.

מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva shares jump as its most promising drug shows exceptional trial results

17.12.24|Sophie Shulman

Duvakitug, designed to treat colitis and Crohn’s disease, exceeded expectations and positions Teva to compete in the $28 billion global market for inflammatory bowel disease treatments.

How dual-listed companies boost profits without earning more

08.12.24|Uri Tal Tenne

The creative accounting tricks Israeli firms use to inflate earnings.

Immunai and Teva launch multi-tear AI collaboration for smarter drug development

14.11.24|CTech

The partnership will utilize Immunai’s cutting-edge immune system mapping tools to enhance precision in immunology and oncology trials.

Teva soars with double-digit growth in Q3, raises annual forecast

06.11.24|Sophie Shulman

Strong sales of Austedo and Ajovy push Teva’s revenues above expectations, with the company forecasting up to $16.5 billion in 2024.

Teva to pay $450 million over Copaxone price inflation

11.10.24|Sophie Shulman

Settlement with the Department of Justice addresses price hikes from $17,000 to $85,000 per year for the multiple sclerosis drug.

Teva's vision 2025: Building on momentum for future market leadership

04.08.24|Sophie Shulman

Richard Francis’ strategic plan aims to transform Teva into a powerhouse of growth and innovation.

Teva posts impressive Q2 results, ups 2024 revenue forecast

31.07.24|Sophie Shulman

Strong sales of Austedo and Ajovy lead to double-digit growth for the Israeli pharma company.

How Monday overtook NICE and why Teva is on course to becoming Israel's highest-valued company

24.07.24|Sophie Shulman

While Wall Street transitions from growth stocks to value stocks, the balance of power among Israeli giants is also shifting. This reflects the speed at which the market punishes companies and rewards those leading growth processes, returning to profitability, or correctly identifying emerging fields.

Teva settles $750 million tax dispute with Israeli authorities

25.06.24|Sophie Shulman

The deal with the Israel Tax Authority resolves all pending litigation related to taxes payable for the years from 2008 to 2020

Teva shares continue to surge, climb to highest mark in more than five years on Q1 results

08.05.24|Sophie Shulman

AUSTEDO continues to be Teva's main growth engine and its flagship drug, with annual growth of 67% in sales

Why are Teva shares surging and how does it plan to keep it up

04.04.24|Uri Tel Tenne

Since the beginning of the year, Teva's shares have risen by about 36%, and are among the best performing stocks on the Tel Aviv Stock Exchange. Why is this happening and how is the company's CEO planning to build on the momentum?

Teva has sights on $12.2 billion Humira market after receiving FDA approval for arthritis injection

25.02.24|Meir Orbach

The Israeli pharma company and Iceland’s Alvotech announced that the SIMLANDI injection has been approved as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis

Teva CEO: "The company played not to lose, now we’ll play to win"

21.02.24|Sophie Shulman

Richard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory

Previous Articles More Articles